Abstract/Summary
Patients with Prader-Willi-Syndrome (PWS) display intellectual impairment, hyperphagia, and various behavioral problems during childhood that converge on a neurologic deficit. The majority of PWS patients have genetic deletions of the paternal 15q11-q13 chromosomal region, with their maternal PWS locus intact but epigenetically silenced by hypermethylation and repressive histone modulation of the PWS imprinting center (PWS-IC). Inhibition of the euchromatin histone methyltransferase G9a by small molecules has been recently reported to reactivate PWS genes in patient fibroblasts and a mouse model. However, it is unknown if inhibition of G9a could have similar effect in human PWS neural cells, the cell types that have direct pathophysiological relevance to PWS. Here, we use neural progenitor cells (NPCs) and cortical excitatory neurons derived from a patient iPSC to model PWS, and quantitatively profile the expression of PWS genes using a NanoString panel. We demonstrated that the methylation of the PWS-IC is stable during neuronal lineage conversion, and that the maternal PWS genes remain silenced in PWS NPCs and neurons. Multiple small molecule inhibitors of G9a activate maternal PWS genes in a dose dependent manner in both NPCs and neurons. In addition, G9a inhibitors induce GNRH1 and HTR2C, two neuronal specific genes that contribute to PWS pathology in neurons. Interestingly, distinct from 5-Azacytidine, G9a inhibition does not induce methylation changes of the maternal PWS-IC, indicating that disruption of the histone repressive complex alone is sufficient to drive an open chromatin state at the PWS-IC that leads to partial reactivation of PWS genes.
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Reactivating PWS genes in neurons by inhibiting G9a Prader-Willi syndrome (PWS) is a developmental disorder in which boys and girls present with developmental delays, including muscle hypotonia, short stature at infancy, intellectual impairment and various behavioral problems during childhood. Most PWS patients exhibit severe hyperphagia and lose appetite control, leading to obesity and type II diabetes (Angulo et al., 2015; Cassidy et al., 2000) when diet is not well-controlled. This combination of traits indicates dysfunction of the neuroendocrine system. In PWS patients, the paternal copy of PWS genes, situated on chromosome 15q11-q13, is missing or silenced. This region includes SNORD116 and SNORD115 snoRNA clusters, SNRPN, SNURF, NDN, MKRN3, and MAGEL2 . These genes are present on the maternal copy of chromosome 15 but silenced by hypermethylation and repressive histone modulation of the PWS imprinting center (PWS-IC) (Cassidy et al., 2000; Fulmer-Smentek and Francke, 2001; Henckel et al., 2009) . Genetic ablation studies in murine models attempting to dissect the genetic underpinnings of PWS have converged on the SNORD116 snoRNA cluster as the major contributor to PWS etiology (Bortolin-Cavaille and Cavaille, 2012; Burnett et al., 2017a; Ding et al., 2008; Gallagher et al., 2002; Polex-Wolf et al., 2018; Qi et al., 2016; Zhang et al., 2012) . However, human genetic and clinical data suggested that other PWS genes, such as NDN, MAGEL2 and SNRPN also contribute to PWS etiology by regulation of hypothalamic neural function (Kuslich et al., 1999; Matarazzo et al., 2017; Miller et al., 2009; Wijesuriya et al., 2017) .
There is currently no cure for PWS, with most clinical efforts focusing on hormonal management to modulate the neuroendocrinal circuit (Angulo et al., 2015; Dykens et al., 2018; Einfeld et al., 2014; Miller et al., 2017; Tauber et al., 2017) . However, owing to relatively clear genetic root cause for PWS, epigenetic activation of the transcriptionally silent maternal PWS genes represents an attractive therapeutic approach. Indeed, 5-Azacytidine (5-Aza), a cytidine analog that antagonizes de novo DNA methylation has been proven to demethylate PWS-IC and substantially reactivate maternal PWS genes in mitotic cells (Saitoh and Wada, 2000; Takano et al., 2007) . In addition, deregulation of the repressive histone methyltransferase SETDB1 by genetic ablation (Cruvinel et al., 2014) , and application of HDAC inhibitors (Saitoh and Wada, 2000) have demonstrated variable effects on PWS gene derepression in mouse models and various human cells. A recent report demonstrated that inhibition of the euchromatin histone methyltransferase G9a by small molecules could reactivate SNORD116 and other PWS genes in PWS patient fibroblasts, consistent with the key role that G9a plays in catalyzing H3K9 dimethylation at the maternal PWS-IC to silence PWS genes. Notably, G9a inhibition also significantly improves the life span of a PWS mouse model, which otherwise will die within 2 weeks after birth (Kim et al., 2017) . Interestingly, both G9a and SETDB1 are histone methyltransferases that methylate H3K9 and have been demonstrated to form a megacomplex that interacts with de novo and maintenance DNA methyltransferases (DNMTs) and thus is linked to PWS-IC methylation and genetic imprinting in rodent development and human iPSCs, although the detailed molecular mechanism remains elusive (FulmerSmentek and Francke, 2001; Henckel et al., 2009; Xin et al., 2003; Zhang et al., 2016) . These findings support the notion that there is a molecular interplay between DNA methylation and heterochromatic modulation of the PWS-IC in maintaining genomic imprinting at the PWS locus.
Modeling genetic disease in vitro using patient derived iPSCs has been a powerful approach to study disease mechanisms (Soldner and Jaenisch, 2018) . A body of work has been reported on in vitro disease modeling for PWS, not only providing valuable patient-derived, genetically accurate disease cell lines for the PWS community, but also elucidating new mechanisms that have valuable clinical implications (Burnett et al., 2016; Chamberlain et al., 2010; Kim et al., 2013; Martins-Taylor et al., 2014; PolvoraBrandao et al., 2018; Takano et al., 2007; Yang et al., 2010) . In the present study, we model PWS using patient-specific iPSC-derived neural progenitor cells (NPCs) and cortical excitatory neurons, and quantitatively profile the expression of PWS genes using a NanoString panel. We demonstrate that methylation of the PWS-IC is stable during neuronal lineage conversion, and that the maternal PWS genes remain silenced in PWS NPCs and neurons. We show that multiple small molecule inhibitors of G9a activate maternal PWS genes in a dose dependent manner in both NPCs and neurons via PWS-IC methylation independent mechanisms. In addition, we found that G9a inhibitors in PWS neurons induce GNRH1 and HTR2C, two neuron specific genes associated with PWS pathology (Miller et al., 2009; GlattDeeley et al., 2010; Garfield et al., 2016) . Our data suggest that deregulation of the H3K9 methyltransferase G9a can partially activate maternal PWS genes in neural progenitors and neurons, the cell types of direct pathophysiological relevance for PWS. We therefore provide proof of concept for activation of critical PWS genes via epigenetic modulation. e  p  a  t  e  r  n  a  l  l  y  -e  x  p  r  e  s  s  e  d  i  m  p  r  i  n  t  e  d  g  e  n  e  s  i  n  t  h  e  P  W  S  r  e  g  i  o  n  r  e  m  a  i  n  r  e  p  r  e  s  s  e  d  i  n  P  W  S  N  P  C  s   a  n  d  n  e  u  r  o  n  s  ,  i  n  d  i  c  a  t  i  n  g  t  h  a  t  t  h  e  g  e  n  e  t  i  c  i  m  p  r  i  n  t  i  n  g  o  f  t  h  e  P  W  S  l  o  c  u  s  i  s  n  o  t  a  l  t  e  r  e  d  d  u  r  i  n  g  n  e  u  r  o  n  a  l   d  i  f  f  e  r  e  n  t  i  a  t  i  o  n  .  I  n  t  e  r  e  s  t  i  n  g  l  y  ,  t  h  e  r  e  l  a  t  i  v  e  e  x  p  r  e  s  s  i  o  n  o  f  t  h  e  s  e  t  r  a  n  s  c  r  i  p  t  s  i  n  P  W  S  c  e  l  l  s  r  e  l  a  t  i  v  e  t  o  W  T  c  e  l  l  s   i  s  d  i  f  f  e  r  e  n  t  b  e  t  w  e  e  n  N  P  C  s  a  n  d  n  e  u  r  o  n  s  ,  s  u  g  g  e  s  t  i  n  g  p  o  s  s  i  b  l  e  c  e  l  l  t  y  p  e  s  p  e  c  i  f  i  c  r  e  g  u  l  a  t  i  o  n  o  f  t  h  e  g  e  n  e  s   w  i  t  h  i  n  t  h  e  P  W  S  l  o  c  u  s  (  F  i  g  u  r  e  2  B  &  C  ) . et al., 2009; Glatt-Deeley et al., 2010; Garfield et al., 2016) . 
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